Galmed Pharmaceuticals에 대한 매도 수량은 투자자에게 Galmed Pharmaceuticals의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Galmed Pharmaceuticals (NASDAQ:GLMD) 주식, 공매도 수량 보고

Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.

Exclusives

Trading Ideas

AAPL

AMZN

APLD

CNEY

GLMD

GOVX

IMRX

INTC

LUMN

LUNR

NDRA

NVDA

PLTR

SMCI

SMMT

TNON

TSLA

WHLR

매일 거래일마다 벤징가 프로(Benzinga Pro)에서 수백 개의 헤드라인과 보도자료가 올라온다. 이는 트레이더들이 전체 시장 및 개별 종목에 대한 최신 뉴스를 확인할 수 있는 소스이다. 2024년 9월에 Benzinga Pro에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 성과는 9월 30일 기준이며 배당금은 포함되지 않았다.

독점: 9월 벤징가 프로에서 가장 많이 검색된 상위 20개 티커 - 테슬라, 엔비디아, 애플은 어디에?

GOLD

매주 ‘벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)&#39;는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 끌고 있는 주식 5종목을 소개한다.

벤징가의 &#39;스톡 위스퍼&#39; 지수: 투자자들이 몰래 주시하지만 아직 말하지 않는 주식 5종목

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals Ltd

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">and individual tickers.</a>
Here is a look at the most-searched stocks on Benzinga Pro for September 2024. Current prices and year-to-date performance are based on Sept. 30 and do not include dividends.
1. NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
<ol></ol>
<ol></ol>
<ol></ol>
<ol></ol>
<ul>
<li>Current Price: $121.44</li>
<li>52-Week Range: $39.23 to $140.76</li>
<li>Year-to-Date Return: +152.1%</li>
<li><a href="https://www.benzinga.com/top-stories/24/07/39579249/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-june-where-do-nvidia-gamestop-tesla-apple">June</a>/<a href="https://www.benzinga.com/top-stories/24/08/40119459/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-july-2024-where-do-tesla-nvidia-apple-crow">July</a>/<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40691773/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-august-2024-where-do-tesla-n">August </a>Ranking: 1st/2nd/1st</li>
</ul>
2. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
<ul>
<li>Current Price: $573.76</li>
<li>52-Week Range: $409.22 to $574.71</li>
<li>Year-to-Date Return: +21.4%</li>
<li>June/July/August Ranking: 3rd/3rd/2nd</li>
</ul>
3. Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
<ul>
<li>Current Price: $261.63</li>
<li>52-Week Range: $138.80 to $271.00</li>
<li>Year-to-Date Return: +5.3%</li>
<li>June/July/August Ranking: 4th/1st/3rd</li>
</ul>
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent100224">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
4. Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
<ul>
<li>Current Price: $233.00</li>
<li>52-Week Range: $164.08 to $237.23</li>
<li>Year-to-Date Return: +25.5%</li>
<li>June/July/August Ranking: 5th/7th/6th</li>
</ul>
5. Wheeler Real Estate Investment Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>)
<ul>
<li>Current Price: $8.09</li>
<li>52-Week Range: $2.90 to $1,126.80</li>
<li>Year-to-Date Return: -92.8%</li>
<li>June/July/August Ranking: Not in Top 20 in any</li>
</ul>
6. Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
<ul>
<li>Current Price: $488.07</li>
<li>52-Week Range: $342.35 to $503.52</li>
<li>Year-to-Date Return: +21.2%</li>
<li>June/July/August Ranking: 11th/11th/9th</li>
</ul>
7. Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
<ul>
<li>Current Price: $416.40</li>
<li>52-Week Range: $226.59 to $1,229.00</li>
<li>Year-to-Date Return: +45.9%</li>
<li>June/July/August Ranking: 10th/19th/4th</li>
</ul>
8. Galmed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>)
<ul>
<li>Current Price: $6.86</li>
<li>52-Week Range: $2.73 to $23.80</li>
<li>Year-to-Date Return: +29.9%</li>
<li>June/July/August Ranking: Not in Top 20 in any</li>
</ul>
9. Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)
<ul>
<li>Current Price: $23.46</li>
<li>52-Week Range: $18.51 to $51.28</li>
<li>Year-to-Date Return: -50.9%</li>
<li>June/July/August Ranking: Not in Top 20 in any</li>
</ul>
10. Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>)
<ul>
<li>Current Price: $8.05</li>
<li>52-Week Range: $2.09 to $13.25</li>
<li>Year-to-Date Return: +241.1%</li>
<li>June/July/August Ranking: Not in Top 20/Not in Top 20/20th</li>
</ul>
Honorable Mentions:&nbsp;The following stocks were the 11th&nbsp;to 20th&nbsp;most-searched tickers on&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;in September 2024.
11. Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)
12. Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)
13. Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)
14. Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>)
15. CN Energy Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNEY#NASDAQ">CNEY</a>)
16. Quhuo Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QH#NASDAQ">QH</a>)
17. ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>):
18. Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>)
19. Immuneering Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>)
20. Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)
Why It&#8217;s Important:&nbsp;Nvidia was the top searched stock on Benzinga Pro for the month of September once again. The stock has ranked first or second for every month tracked since February, sometimes alternating with SPY or Tesla.
The SPDR S&amp;P 500 ETF Trust ranked second for a second straight month, which comes as the S&amp;P 500 tracking index hit new all-time highs in the month of September.
Tesla, which topped the month of July, has ranked third for two straight weeks. The stock has ranked among the top four stocks searched in each month tracked in 2024.
The bigger story in September were the newcomers and the stocks that dropped off.
Newcomers to the top 10 included Wheeler Real Estate, Galmed, Intel and Intuitive. Of the four stocks, only Intuitive had ranked in the top 20 over the last three months. The newcomers all had catalysts in the last month that made their stocks highly volatile.
On the 11th through 20th portion of the list, the stocks were all different from the previous month with Intuitive moving to the top 10 and Palantir going from 7th to 12th and the other stocks all new to the top 20.
Several of the companies ranked in the bottom part of the top 20 are penny stocks trading at less than $5 per share that saw wide moves that saw increased interest from Benzinga traders.
One of the bigger names to make the top 20, by name recognition, is Trump Media &amp; Technology Group, the company that counts former President Donald Trump as a co-founder. The stock has been highly volatile during the 2024 election cycle.
Dropping out of the top 10 were Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>), Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) and the aforementioned Palantir.
Other big names that exited the top 20 include Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) that was 13th in August and fell to 24th to narrowly miss the list.
Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), which has frequently appeared in the top 20 and was ranked 15th in August dropped out of the top 20.
Overall the month of September saw six of the same top 10 tickers from August and eight of the top 20 tickers from August.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/exclusives/24/07/39603613/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-first-half-2024-where-do-nvidia-tesla-pala">EXCLUSIVE: Top 10 Most Searched Tickers On Benzinga Pro In First Half 2024 – Where Do Nvidia, Tesla, Palantir, GameStop Rank?</a></li>
</ul>
Image: Shutterstock

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?

WIIM

Galmed Pharmaceuticals shares are trading lower. The company announced that results of its Phase 3 trial of Aramchol in 150 patients with NASH and fibrosis has been published in Hepatology.

<ul>
<li>The paper re-iterates the significant&nbsp;anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH)</li>
<li>Data is confirmed using 3 objective measurements; NASH&nbsp;CRN, paired ranked reading, and Artificial Intelligence (AI) quantitative digital analysis</li>
<li>Continuous&nbsp;histological fibrosis scores generated in antifibrotic trials by digital pathology images analysis (DIA) quantify antifibrotic effects with greater sensitivity and larger dynamic range than Conventional Pathology</li>
</ul>
TEL AVIV, Israel, Sept. 25, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibro-inflammatory diseases announced today that the one-year results of the Open-Label part (ARCON ) of its global Phase 3 trial of Aramchol in 150 patients with NASH and fibrosis (ARMOR) have been published in&nbsp;<a href="https://journals.lww.com/hep/abstract/9900/aramchol_improves_hepatic_fibrosis_in_metabolic.930.aspx">Hepatology</a>.&nbsp;

Biotech

News

General

Galmed 1-Year Results Of The Open-Label Part Of Its Global Phase 3 Trial Of Aramchol In 150 Patients With NASH And Fibrosis Have Been Published In Hepatology

Insider Trades

Masaya Otsuka Reported a 9.9% Passive Stake In Galmed Pharmaceuticals In A 13G Filing

Each week,&nbsp;Benzinga's Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Here&#8217;s a look at the Benzinga Stock Whisper Index for the week of Sept. 20:
Barrick Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>): The gold-mining company saw increased interest from readers this week on the heels of a 50 basis point cut to interest rates by the Federal Reserve, which saw gold prices rise. The interest also comes after Barrick Gold CEO Mark Bristow spoke at the Gold Forum Americas earlier this week and<a href="https://www.benzinga.com/news/24/09/40915786/barrick-forecasts-strong-organic-growth-by-2030-ceo-bristow-touts-undervaluation"> said the company expects </a>30% growth in gold-equivalent ounces by the end of the decade from its existing assets. 
Bristow's comments emphasized the company's current mines and those in development, as the industry experiences a surge in merger and acquisition activity. The CEO also highlighted how the company is expanding its copper portfolio, which could be something exciting to watch for investors.
Barrick shares were down 2% over the last five trading days, as seen on the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1">Benzinga Pro chart</a> below. The stock is up 14% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="483" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183.png" alt="" class="wp-image-558808" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183-768x371.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Galmed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>): The biopharmaceutical company <a href="https://www.benzinga.com/news/24/09/40941193/galmed-pharmaceuticals-stock-is-soaring-thursday-heres-why">saw shares soar </a>during the week after an announcement on drug development activities. Galmed plans to add drug developments that target cardiac fibrosis and colorectal and hepatic cancers. The company will release data from the studies during the fourth quarter.
"The conditions Galmed plans to focus upon in the coming years are major public health problems impacting millions of people worldwide and posing huge financial burden on health providers," Galmed CEO Allen Baharaff said.
Large interest in Galmed saw shares halted several times during the trading week. Helping with volatility in the biopharmaceutical company is the low-float of the stock with around 625,000 shares available according to Benzinga Pro. Low-float stocks can often see high volatility on company announcements.
The stock was up 160% over the last five days and up nearly 100% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184.png" alt="" class="wp-image-558810" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184-768x388.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Read Also:&nbsp;<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40691773/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-august-2024-where-do-tesla-n" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In August 2024 – Where Do Tesla, Nvidia, Apple, AMD Stock Rank?</a>
ServiceNow Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>): The software company is seeing a large increase in interest from readers ahead of its third-quarter financial results. Analysts expect the company to report revenue of $2.74 billion, up from $2.29 billion in last year's third quarter.
The company has beaten analyst revenue estimates in six straight quarters. Analysts expect the company to report earnings per share of $3.46, up from $2.92 in last year's third quarter. ServiceNow has beaten earnings estimates from analysts in more than 20 straight quarters.
The company's earnings report will show investors and analysts whether revenue growth and AI platform demand are continuing to strengthen. The company saw subscription revenue up 23% year-over-year in <a href="https://www.benzinga.com/news/earnings/24/07/39944577/servicenow-q2-earnings-revenue-beat-eps-beat-servicenow-intends-to-reinvent-every-workflow-in-every">the second quarter </a>and said it was helping meet demand from CEOs looking for new growth as ServiceNow reinvents "every workflow, in every company, in every industry with GenAI at the core."
ServiceNow shares are up 4% over the last five days and up 34% year-to-date.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="514" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185.png" alt="" class="wp-image-558811" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185-768x396.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Deutsche Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>): It's not every week that a bank stock makes its way on the Stock Whisper Index, but here we are. Deutsche Bank saw strong interest from readers, which could be due to bank stocks getting a lift after the <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40928301/interest-rates-in-free-fall-what-it-means-for-mortgages-credit-cards-and-your-wallet-a">interest rate cut was announced.</a> 
The move could see lenders have their balance sheets strengthened going forward and see increased demand for loan activity. Deutsche Bank reports third-quarter financial results in October and could comment on demand and what the future looks like for the company and the sector.
Shares were up 5% over the last five days and 24% year-to-date.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="504" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186.png" alt="" class="wp-image-558812" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186-768x387.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Stryker Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>): The medical equipment company saw strong interest from readers during the week, which comes on the heels of acquisition announcements, new products <a href="https://www.benzinga.com/quote/SYK/analyst-ratings">and analyst notes</a>. 
The company recently unveiled new foot and ankle solutions that can help restore limb length. Stryker closed its acquisition of privately held care.ai, a company helping with AI-assisted virtual care workflows and smart room technology. The company said the acquisition will help accelerate its digital vision and could expand its healthcare IT business. 
On Friday, Stryker closed its acquisition of NICO Corporation, a company with a surgery method for tumor and intracerebral hemorrhage procedures. Stryker also announced an acquisition of pain management company Vertos Medical in August. Together, the acquisitions and new products could have investors excited about the company's future and its potential diversification efforts.
Piper Sandler recently maintained an Overweight rating and a $380 price target on the stock. Wolfe Research initiated coverage with an Outperform rating and a $405 price target.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187.png" alt="" class="wp-image-558813" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187-768x387.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Stay tuned for next week's report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40420145/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 16</a></li>
<li><a href="https://www.benzinga.com/top-stories/24/08/40531771/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 23</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/08/40653930/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 30</a></li>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40752686/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">September 6</a></li>
<li><a href="https://www.benzinga.com/top-stories/24/09/40855829/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">September 13 </a></li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40838414/gold-miners-eye-best-1-day-rally-in-6-months-as-gold-hits-fresh-record-highs-todays-environment-">Gold Miners Eye Best 1-Day Rally In 6 Months As Gold Hits Fresh Record Highs: &#8216;Today&#8217;s Environment Closely Resembles The 1970s&#8217;</a></li>
</ul>
Photo: Benzinga

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Galmed Pharmaceuticals Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) shares are surging Thursday after the company&nbsp;announced plans to broaden its drug development activities <a href="https://www.benzinga.com/pressreleases/24/09/n40935244/galmed-announces-an-expansion-of-its-activities-to-cancer-and-major-cardiometabolic-diseases">over the next two years</a>.
What Happened: Galmed announced that it plans to expand its drug development activities by adding two additional programs.
One program aims to identify novel Aramchol-based drug combinations to overcome resistance to standard-of-care oncological treatments for patients with advanced colorectal and hepatic cancers. The other program is expected to help discover new methods to allow the development of a novel Aramchol-based drug combination targeting cardiac fibrosis.
The clinical-stage biopharmaceutical company said it&nbsp;plans to release new data from in-vitro and ex-vivo studies on the aforementioned programs during the&nbsp;fourth quarter.
&#8220;The conditions Galmed plans to focus upon in the coming years are major public health problems impacting millions of people worldwide and posing huge financial burden on health providers,&#8221; said Allen Baharaff, president and CEO of Galmed Pharmaceuticals.
&#8220;SCD1 is a key enzyme that critically regulates many physiological processes, thereby promoting the progression of cardiovascular, cancer and neurodegenerative diseases. We are leveraging on two decades of development of the most clinically advanced SCD1 inhibitor (Aramchol) to date as we broaden our drug development activities.&#8221;
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40939795/1-8m-bet-on-singular-genomics-check-out-these-3-stocks-executives-are-buying">$1.8M Bet On Singular Genomics? Check Out These 3 Stocks Executives Are Buying</a>
Galmed Pharmaceuticals is a very low-float stock with approximately 625,000 shares available for public trading, per&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.&nbsp;The company also had a market cap of less than $4.5 million as of Wednesday's close.&nbsp;Low-float, micro-cap stocks can be extremely volatile, which may help explain some of Thursday's surge.
Galmed&#8217;s average session volume over a 100-day period is approximately 1.711 million. Thursday&#8217;s trading volume has already crossed 16 million at the time of writing, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
GLMD Price Action: <a href="http://benzinga.com/quote/glmd">Galmed shares</a> were up 53.6% at $10.60 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: 3844328 from Pixabay.

Movers

Galmed Pharmaceuticals Stock Is Soaring Thursday: Here's Why

Galmed Pharmaceuticals Shares Resumed Trade

Galmed Pharmaceuticals Shares Halted To The Upside; Stock Now Up 67.54%

Galmed Pharmaceuticals shares are trading higher after the company announced plans to broaden its drug development activities with two additional programs over the next two years.

GLMD: 60% &#x7C; <a href="https://www.benzinga.com//node/40935862">Galmed Pharmaceuticals Plans To Broaden Its Drug Development Activities, Consisting Of Two Additional Programs Over The Next Two Years</a>
&nbsp;
EWTX: 42% &#x7C; <a href="https://www.benzinga.com//node/40935611">Edgewise Therapeutics Announced Top-line Data Of EDG-7500 From The Phase 1 Trial In Healthy Subjects And The Single-dose Arm Of Phase 2 CIRRUS-HCMtrial In Patients With Obstructive Obstructive Hypertrophic Cardiomyopathy</a>
&nbsp;
XCUR: 271% &#x7C; <a href="https://www.benzinga.com//node/40927738">Exicure shares are trading higher after the company announced it received an extension from the Nasdaq Hearings Panel.</a>

EWTX

XCUR

Market-Moving News for September 19th

<ul>
<li>One program aims to identify novel Aramchol-based drug combinations to overcome resistance to standard-of-care oncological treatments for patients with advanced colorectal and hepatic cancers.&nbsp;</li>
<li>Another program aims to unravel new mechanisms of action that will allow the development of a novel Aramchol-based drug combination targeting cardiac fibrosis, or scarring of the heart, which occurs in many cardiovascular diseases that can lead to heart dysfunction and failure.&nbsp;</li>
<li>The Company plans on releasing new data from in-vitro and ex-vivo studies in these programs during the fourth quarter of 2024.</li>
</ul>

Health Care

Galmed Pharmaceuticals Plans To Broaden Its Drug Development Activities, Consisting Of Two Additional Programs Over The Next Two Years

U.S. stocks traded mixed this morning, with the Dow Jones index falling over 50 points on Wednesday.
Following the market opening Wednesday, the Dow traded down 0.17% to 41,536.53 while the NASDAQ rose 0.14% to 17,653.56. The S&amp;P 500 also fell, dropping, 0.01% to 5,634.39.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/09/40917630/how-to-earn-500-a-month-from-darden-restaurants-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Darden Restaurants Stock Ahead Of Q1 Earnings</a>
Leading and Lagging Sectors Energy shares jumped by 0.3% on Wednesday.
In trading on Wednesday, health care shares fell by 0.2%.
Top Headline
General Mills, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) reported better-than-expected earnings for its first quarter on Wednesday.
The company reported first-quarter adjusted earnings per share of $1.07 (down 2%), beating the street view of $1.06. Quarterly revenues of $4.85 billion outpaced the analyst consensus estimate of $4.801 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares shot up 185% to $12.92 after jumping around 15% on Tuesday.</li>
<li>Shares of Odyssey Marine Exploration, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) got a boost, surging 126% to $1.12 after declining around 89% on Tuesday.</li>
<li>Webuy Global Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBUY#NASDAQ">WBUY</a>) shares were also up, gaining 97% to $0.2294. Webuy Global, on Tuesday, reported a year-over-year increase in interim H1 revenue results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Galmed Pharmaceuticals Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) shares dropped 34% to $9.98 after jumping 290% on Tuesday.</li>
<li>Shares of BurgerFi International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>) were down 29% to $0.1651. BurgerFi recently received interim approval for $3.5 million in financing to support 144 locations during its restructuring.</li>
<li>Cibus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) was down, falling 23% to $3.90 after the company announced the pricing of $12 million offering of 3 million shares at $4.00 per share.</li>
</ul>
Commodities In commodity news, oil traded down 0.7% to $70.70 while gold traded up 0.4% at $2,603.60.
Silver traded up 0.1% to $30.98 on Wednesday, while copper rose 0.6% to $4.2965.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.35%, Germany's DAX rose 0.08% and France's CAC 40 fell 0.40%. Spain's IBEX 35 Index fell 0.13%, while London's FTSE 100 fell 0.61%.
Annual inflation rate in the Eurozone fell to 2.2% in August, recording the lowest level since July 2021, compared to 2.6% in the prior month. Construction output in the Eurozone fell by 2.2% year-over-year in July compared to a revised 1.3% decline in the previous month.
Annual inflation rate in the UK came in unchanged at 2.2% in August, in line with estimates, while producer prices increased 0.2% year-over-year in August.
Asia Pacific Markets
Asian markets closed mostly higher on Wednesday, with Japan's Nikkei 225 gaining 0.49%, China's Shanghai Composite Index gaining 0.49% and India's BSE Sensex falling 0.16%.
Japanese trade deficit shrank to JPY 695.30 billion in August from JPY 940.10 billion in the year-earlier month, and versus market expectations of a JPY 1,380 billion gap.
Economics
<ul>
<li>U.S. mortgage applications surged by 14.2% from the prior week in the week ending Sept. 13.</li>
<li>Housing starts in the U.S. climbed by 9.6% from the prior month to an annualized rate of 1.356 million units for August.</li>
<li>U.S. building permits gained by 4.9% to an adjusted annual rate of 1.475 million in August.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40917190/jim-cramer-labels-moderna-a-big-disappointment-but-suggests-doubling-down-on-another-pha">Jim Cramer Labels Moderna A &#8216;Big Disappointment,&#8217; But Suggests Doubling Down On Another Pharma Powerhouse</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

CBUS

OMEX

PRTG

WBUY

US Stocks Mixed; General Mills Posts Upbeat Earnings

Shares of Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) rose sharply in today's pre-market trading after the company announced it was awarded a NASA Near Space Network contract for communication and navigation services, with a maximum <a href="https://www.benzinga.com/news/24/09/40910237/why-intuitive-machines-stock-is-blasting-off-in-extended-trading">potential value of $4.82 billion</a>.
Intuitive Machines shares jumped 41.1% to $7.62 in the pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) gained 231% to $15.02 in pre-market trading after jumping around 15% on Tuesday.</li>
<li>Odyssey Marine Exploration, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) rose 89.3% to $0.9395 in today's pre-market trading after declining around 89% on Tuesday.</li>
<li>Veea Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEA#NASDAQ">VEEA</a>) gained 66.4% to $8.82 in the pre-market trading session after dipping 42% on Tuesday.</li>
<li>Agrify Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGFY#NASDAQ">AGFY</a>) gained 42.8% to $0.36 in pre-market trading.</li>
<li>Webuy Global Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBUY#NASDAQ">WBUY</a>) rose 27.2% to $0.1475 in pre-market trading. Webuy Global, on Tuesday, reported a year-over-year increase in interim H1 revenue results.</li>
<li>VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>) shares rose 24% to $1.55 in pre-market trading. VivoPower shares dipped 35% on Tuesday after the company announced a heads of agreement to merge with Future Automotive Solutions and Technologies.</li>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) gained 21.7% to $2.80 in pre-market trading after gaining 17% on Tuesday.</li>
<li>Windtree Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) gained 21.6% to $3.89 in pre-market trading. On Sept. 4, Windtree Therapeutics completed enrollment of its Phase 2b study of Istaroxime in early cardiogenic shock caused by heart failure.</li>
<li>MKDWELL Tech Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKDW#NASDAQ">MKDW</a>) rose 9.8% to $1.23 in pre-market trading after dipping around 6% on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) fell 32.9% to $10.13 in pre-market trading after jumping 290% on Tuesday.</li>
<li>Smith Micro Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMSI#NASDAQ">SMSI</a>) shares dipped 22.8% to $0.88 in pre-market trading after surging 118% on Tuesday.</li>
<li>Healthcare Triangle, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) fell 17.2% to $0.3766 in pre-market trading after surging 42% on Tuesday.</li>
<li>XCHG Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCH#NASDAQ">XCH</a>) shares fell 15.3% to $9.40 in pre-market trading after gaining 34% on Tuesday.</li>
<li>Tenon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares declined 14.2% to $5.36 in pre-market trading after dipping 19% on Tuesday. Tenon Medical announced the closing of $4.5 million public offering priced at-the-market under Nasdaq rules.</li>
<li>Energous Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) shares declined 14.2% to $0.6437 in pre-market trading.</li>
<li>IO Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) declined 12.6% to $1.04 in pre-market trading after gaining around 54% on Tuesday. IO Biotech recently announced promising data from the Phase 2 basket trial of IO102-IO103, the company&#8217;s lead investigational therapeutic cancer vaccine candidate, in combination with Merck&#8217;s anti-PD-1 therapy KEYTRUDA at the 2024 ESMO Congress.</li>
<li>22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) fell 11.7% to $0.2430 in today's pre-market trading after declining 14% on Tuesday. The company's CEO Lawrence Firestone, last week, disclosed the purchase of shares.</li>
<li>iSpecimen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares fell 7% to $4.79 in pre-market trading after gaining around 14% on Tuesday.</li>
<li>Newegg Commerce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) shares fell 4% to $0.83 in pre-market trading after jumping around 15% on Tuesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/09/40898216/cramer-hewlett-packard-is-a-very-inexpensive-stock-likes-this-big-tech-stock">Cramer: Hewlett Packard Is A &#8216;Very Inexpensive&#8217; Stock, Likes This Big Tech Stock</a></li>
</ul>

Pre-Market Outlook

AGFY

EFSH

HCTI

IOBT

ISPC

MKDW

NEGG

SMSI

VEEA

VVPR

WATT

WINT

XXII

Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket

Galmed Pharmaceuticals Ltd. Shares Resume Trade

Galmed Pharmaceuticals Shares Halted On Circuit Breaker To The Downside, Stock Now Up 372.6%

U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining around 0.2% on Tuesday.
The Dow traded up 0.01% to 41,628.39 while the NASDAQ rose 0.19% to 17,624.93. The S&amp;P 500 also rose, gaining, 0.03% to 5,634.76.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/09/40896687/how-to-earn-500-a-month-from-fedex-stock-ahead-of-q1-earnings">How To Earn $500 A Month From FedEx Stock Ahead Of Q1 Earnings</a>
Leading and Lagging Sectors Energy shares jumped by 1.3% on Tuesday.
In trading on Tuesday, health care shares fell by 1.1%.
Top Headline
The NAHB/Wells Fargo Housing Market Index climbed to 41 in September versus 39 in the prior month.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>BurgerFi International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>) shares shot up 88% to $0.23 after the company received interim approval for $3.5 million in financing to support 144 locations during its restructuring.</li>
<li>Shares of Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) got a boost, surging 422% to $20.19. Galmed Pharmaceuticals regained Nasdaq compliance.</li>
<li>Compass Minerals International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) shares were also up, gaining 24% to $11.40 after the company announced preliminary third-quarter revenue above estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Tupperware Brands Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TUP#NYSE">TUP</a>) shares dropped 58% to $0.5099 following a report suggesting the company is planning bankruptcy.</li>
<li>Shares of Netcapital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCPL#NASDAQ">NCPL</a>) were down 29% to $2.0450 following first-quarter earnings.</li>
<li>Korro Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) was down, falling 8% to $37.42. HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterated Korro Bio with a Buy rating and maintained a $100 price target. The company, on Monday, announced a collaboration with Novo Nordisk to advance the discovery and development of new genetic medicines, with the initial target to treat cardiometabolic diseases.</li>
</ul>
Commodities In commodity news, oil traded up 1.6% to $71.21 while gold traded down 0.4% at $2,597.30.
Silver traded down 0.3% to $31.05 on Tuesday, while copper rose 0.1% to $4.2760.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.40%, Germany's DAX rose 0.50% and France's CAC 40 gained 0.51%. Spain's IBEX 35 Index rose 1.06%, while London's FTSE 100 rose 0.38%.
The ZEW Indicator of Economic Sentiment for the Eurozone fell 8.6 points to an eleven-month low level of 9.3. The ZEW Indicator of Economic Sentiment for Germany fell to 3.6 in September from 19.2 in August.
Asia Pacific Markets
Asian markets closed mostly higher on Tuesday, with Japan's Nikkei 225 falling 1.03%, Hong Kong's Hang Seng Index gaining 1.37% and India's BSE Sensex gaining 0.11%.
The merchandise trade deficit in India increased to $29.7 billion in August, recording the highest level in ten months. India's wholesale prices rose by 1.31% year-over-year in August compared to a 2.04% rise in the prior month.
Economics
<ul>
<li>U.S. retail sales rose 0.1% month-over-month in August compared to revised 1.1% gain in July, and topping market estimates of a 0.2% decline.</li>
<li>The NAHB/Wells Fargo Housing Market Index climbed to 41 in September versus 39 in the prior month.</li>
<li>Total business inventories rose by 0.4% month-over-month in July compared to a 0.3% gain in June and topping market expectations of a 0.3% increase.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/09/40897858/top-2-tech-and-telecom-stocks-that-may-keep-you-up-at-night-in-september">Top 2 Tech And Telecom Stocks That May Keep You Up At Night In September</a></li>
</ul>

Earnings

KRRO

NCPL

Gold Edges Lower; US Homebuilder Sentiment Rises For September

Galmed Pharmaceuticals Shares Resume Trading

Galmed Pharmaceuticals Shares Resume Trade, Then Halted On Circuit Breaker This Time To The Downside, Stock Now Up 264.6%

Galmed Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 307.2%

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 100 points on Tuesday.
The Dow traded up 0.26% to 41,728.28 while the NASDAQ rose 0.73% to 17,721.04. The S&amp;P 500 also rose, gaining, 0.39% to 5,655.10.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/09/40896687/how-to-earn-500-a-month-from-fedex-stock-ahead-of-q1-earnings">How To Earn $500 A Month From FedEx Stock Ahead Of Q1 Earnings</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 1.6% on Tuesday.
In trading on Tuesday, health care shares fell by 0.2%.
Top Headline
U.S. total business inventories rose by 0.4% month-over-month in July compared to a 0.3% gain in June and topping market expectations of a 0.3% increase.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>BurgerFi International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>) shares shot up 96% to $0.2375 after the company received interim approval for $3.5 million in financing to support 144 locations during its restructuring.</li>
<li>Shares of Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) got a boost, surging 99% to $7.72. Galmed Pharmaceuticals regained Nasdaq compliance.</li>
<li>Compass Minerals International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) shares were also up, gaining 28% to $11.77 after the company announced preliminary third-quarter revenue above estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Tupperware Brands Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TUP#NYSE">TUP</a>) shares dropped 58% to $0.5099 following a report suggesting the company is planning bankruptcy.</li>
<li>Shares of Netcapital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCPL#NASDAQ">NCPL</a>) were down 26% to $2.1438 following first-quarter earnings.</li>
<li>Korro Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) was down, falling 7% to $38.10. HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterated Korro Bio with a Buy rating and maintained a $100 price target. The company, on Monday, announced a collaboration with Novo Nordisk to advance the discovery and development of new genetic medicines, with the initial target to treat cardiometabolic diseases.</li>
</ul>
Commodities In commodity news, oil traded up 1.4% to $71.08 while gold traded down 0.1% at $2,608.40.
Silver traded up 0.6% to $31.31 on Tuesday, while copper rose 0.2% to $4.2865.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.52%, Germany's DAX rose 0.62% and France's CAC 40 gained 0.52%. Spain's IBEX 35 Index rose 1.22%, while London's FTSE 100 rose 0.43%.
The ZEW Indicator of Economic Sentiment for the Eurozone fell 8.6 points to an eleven-month low level of 9.3. The ZEW Indicator of Economic Sentiment for Germany fell to 3.6 in September from 19.2 in August.
Asia Pacific Markets
Asian markets closed mostly higher on Tuesday, with Japan's Nikkei 225 falling 1.03%, Hong Kong's Hang Seng Index gaining 1.37% and India's BSE Sensex gaining 0.11%.
The merchandise trade deficit in India increased to $29.7 billion in August, recording the highest level in ten months. India's wholesale prices rose by 1.31% year-over-year in August compared to a 2.04% rise in the prior month.
Economics
<ul>
<li>U.S. retail sales rose 0.1% month-over-month in August compared to revised 1.1% gain in July, and topping market estimates of a 0.2% decline.</li>
<li>The NAHB/Wells Fargo Housing Market Index climbed to 41 in September versus 39 in the prior month.</li>
<li>Total business inventories rose by 0.4% month-over-month in July compared to a 0.3% gain in June and topping market expectations of a 0.3% increase.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/09/40897858/top-2-tech-and-telecom-stocks-that-may-keep-you-up-at-night-in-september">Top 2 Tech And Telecom Stocks That May Keep You Up At Night In September</a></li>
</ul>

Crude Oil Gains Over 1%; US Business Inventories Increase In July

Galmed Pharmaceuticals (GLMD) has released an update. Galmed Pharmaceuticals Ltd. successfully conducted its Annual General Meeting on July 17, 202...

Galmed Shareholders Approve Key Resolutions

Galmed Pharmaceuticals (GLMD) has released an update. Galmed Pharmaceuticals Ltd. has announced a reverse stock split at a ratio of 1-for-12, effec...

Galmed Pharmaceuticals Announces Reverse Stock Split

Galmed Pharmaceuticals (GLMD) has released an update. Galmed Pharmaceuticals Ltd. reports a net loss of $2.394 million for the first half of 2024, ...

Galmed Pharmaceuticals Reports Mid-Year Loss

Galmed Pharmaceuticals (GLMD) has released an update. Galmed Pharmaceuticals Ltd., an Israeli company, has entered into a Standby Equity Purchase A...

Galmed Pharmaceuticals Secures $10M Equity Agreement

Galmed Pharmaceuticals files to sell 416,667 of ordinary shares for holders

Galmed Pharmaceuticals (GLMD) has released an update. Galmed Pharmaceuticals Ltd. has successfully regained compliance with Nasdaq's minimum bid pr...

Galmed Pharmaceuticals Regains Nasdaq Compliance

Galmed Pharmaceuticals ($GLMD), a biotech company based in Tel Aviv, saw its stock skyrocket by almost 500% on Tuesday, following news that it had ...

Galmed Pharmaceuticals Soars Nearly 500% Amid Nasdaq Compliance and Short Squeeze

Galmed Pharmaceuticals (GLMD) has released an update. Galmed Pharmaceuticals is broadening its horizons by expanding its drug development activitie...

Galmed Targets Cancer and Heart Disease

Galmed Pharmaceuticals (GLMD) has released an update. Galmed Pharmaceuticals is inviting shareholders to a Special General Meeting on October 14, 2...

Galmed Pharmaceuticals Calls for Capital Increase Vote

Galmed Pharmaceuticals (GLMD) has released an update. Galmed Pharmaceuticals has published promising one-year results of the ARCON Phase 3 trial in...

Galmed Reports Breakthrough in MASH Treatment

Press Releases

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Small Cap

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

Comments

Galmed Pharmaceuticals

매도 수량

Galmed Pharmaceuticals (NASDAQ:GLMD) 주식, 공매도 수량 보고

뉴스

파트너 / 기고자

벤징가 글로벌